|1.||Guillemin, Gilles J: 21 articles (01/2015 - 01/2002)|
|2.||Brew, Bruce J: 15 articles (09/2014 - 01/2002)|
|3.||Kumar, Anil: 11 articles (12/2014 - 11/2009)|
|4.||Vandresen-Filho, Samuel: 9 articles (08/2015 - 12/2007)|
|5.||Kalonia, Harikesh: 8 articles (11/2012 - 11/2009)|
|6.||Souza, Diogo O: 8 articles (02/2010 - 08/2003)|
|7.||Schwarcz, Robert: 7 articles (08/2015 - 01/2003)|
|8.||Heyes, Melvyn P: 7 articles (04/2013 - 07/2002)|
|9.||Tasca, Carla I: 6 articles (09/2014 - 04/2005)|
|10.||Kumar, Puneet: 6 articles (03/2011 - 11/2009)|
|1.||Huntington Disease (Huntington's Disease)
11/01/2000 - "Intrastriatal injection of quinolinate has been proven to be a very useful animal model to study the pathogenesis and treatment of Huntington's disease. "
12/01/2003 - "Deficits induced by quinolinic acid lesion to the striatum in a position discrimination and reversal task are ameliorated by permanent and temporary lesion to the globus pallidus: a potential novel treatment in a rat model of Huntington's disease."
03/16/1998 - "Electrolytic lesion of globus pallidus ameliorates the behavioral and neurodegenerative effects of quinolinic acid lesion of the striatum: a potential novel treatment in a rat model of Huntington's disease."
06/01/2015 - "In the present study, the effect of treadmill exercise on spatial-learning ability and motor coordination focusing on the apoptosis in the hippocampus was investigated using quinolinic acid-induced Huntington's disease rats. "
02/15/2013 - "The present study was designed to examine the correlations between behavioural and oxidative parameters in a quinolinic acid model of Huntington's disease in rats. "
01/01/1986 - "The effect of pretreatment with drugs on generalized clonic-tonic seizures induced by intracerebroventricular (i.c.v.) administration of the endogenous convulsant quinolinic acid (QUIN, 50 micrograms) was studies in rats. "
09/01/2014 - "Aloysia gratissima aqueous extract (AE) was investigated as a putative protective agent against quinolinic acid (QA)-induced seizures in mice and hippocampal cell damage. "
06/01/2014 - "Microinjections of quinolinic acid (10 micrograms) or electrical stimulation with 70 Hz frequency produced the paroxysmal manifestations in the form of intensive circular excursions coincident wild running behaviors on the initial nonseizures motor exitation stage of audiogenic seizures. "
02/01/2012 - "ConBr, a lectin from Canavalia brasiliensis seeds, protects against quinolinic acid-induced seizures in mice."
10/01/1995 - "Animals that were given quinolinate did not display behavioral seizures, and showed preferential degeneration of neurons in layer V of the entorhinal cortex. "
|3.||Body Weight (Weight, Body)
01/01/2010 - "The optimal dose of Ksheerabala was found from a dose escalation study, wherein it was found that Ksheerabala showed maximum protection against quinolinic acid-induced neurotoxicity at a dose of 15 microL/100 g body weight/day, which was selected for further experiments. "
01/01/2010 - "Four groups of female albino rats were maintained for 21 days as follows: 1. Control group, 2. Quinolinic acid (55 microg/100 g body weight), 3. Ksheerabala (15 microL/100 g body weight), 4. Ksheerabala (15 microL/100 g body weight) + Quinolinic acid (55 microg/100 g body weight). "
10/01/1997 - "In gerbils, systemic immune activation by an intraperitoneal injection of endotoxin (1 mg/kg of body weight) increased quinolinate levels in brain, blood, lung, liver, and spleen, with proportional increases in lung indoleamine-2,3-dioxygenase activity at 24 h postinjection. "
03/30/2011 - "Licofelone (2.5, 5 and 10 mg/kg) treatment significantly improved body weight, locomotor activity, rotarod performance, balance beam walk performance, oxidative defense, mitochondrial enzyme complex activities and attenuated TNF-α level and striatal lesion as compared to control (quinolinic acid). "
04/25/2011 - "Intrastriatal quinolinic acid (300 nmol) administration significantly altered the body weight, motor coordination, and induced oxidative damage (as indicated by the increase in lipid peroxidation and nitrite concentration) in the striatum as compared to sham group. "
|4.||Acquired Immunodeficiency Syndrome (AIDS)
12/01/1995 - "Quinolinic acid and neurodegeneration in AIDS."
06/01/1993 - "Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains."
08/01/1989 - "It remains to be determined whether increased brain quinolinic acid concentrations are involved in the pathogenesis of the neuropathology of AIDS."
08/01/1989 - "Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome."
04/01/1998 - "This may lead to changes in quinolinic acid and explain some of the pathogenesis of AIDS dementia."
|5.||Nervous System Diseases (Neurological Disorders)
01/01/2014 - "The outcome of this study provides a new insight into therapeutic strategies for limiting quinolinic acid-induced neurodegeneration, especially in neurological disorders that target oligodendrocytes, such as MS. "
05/31/2005 - "Quinolinate has also been implicated in important neurological disorders. "
06/01/2001 - "Because minor changes in the physiological concentrations of 3OH-kynurenine and quinolinic acid may cause neuronal death, our data suggest that these metabolites play a key role in the pathogenesis of several neurological disorders."
04/01/1996 - "Quinolinic acid (Quin) is thought to underlie cognitive and motor dysfunctions for a variety of neurological disorders. "
10/01/1997 - "Quinolinic acid (QUIN) has been associated with several inflammatory neurologic disorders, including AIDS dementia complex (ADC). "
|4.||salicylhydroxamic acid (SHAM)
|7.||Dizocilpine Maleate (Dizocilpine)
|1.||Transplantation (Transplant Recipients)
|5.||Homologous Transplantation (Allograft)